Now showing items 48-67 of 838

    • Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. 

      Telomeres Mendelian Randomization Collaboration; Haycock, PC; Burgess, S; Nounu, A; Zheng, J; Okoli, GN; Bowden, J; Wade, KH; Timpson, NJ; Evans, DM; Willeit, P; Aviv, A; Gaunt, TR; Hemani, G; Mangino, M; Ellis, HP; Kurian, KM; Pooley, KA; Eeles, RA; Lee, JE; Fang, S; Chen, WV; Law, MH; Bowdler, LM; Iles, MM; Yang, Q; Worrall, BB; Markus, HS; Hung, RJ; Amos, CI; Spurdle, AB; Thompson, DJ; O'Mara, TA; Wolpin, B; Amundadottir, L; Stolzenberg-Solomon, R; Trichopoulou, A; Onland-Moret, NC; Lund, E; Duell, EJ; Canzian, F; Severi, G; Overvad, K; Gunter, MJ; Tumino, R; Svenson, U; van Rij, A; Baas, AF; Bown, MJ; Samani, NJ; van t'Hof, FNG; Tromp, G; Jones, GT; Kuivaniemi, H; Elmore, JR; Johansson, M; Mckay, J; Scelo, G; Carreras-Torres, R; Gaborieau, V; Brennan, P; Bracci, PM; Neale, RE; Olson, SH; Gallinger, S; Li, D; Petersen, GM; Risch, HA; Klein, AP; Han, J; Abnet, CC; Freedman, ND; Taylor, PR; Maris, JM; Aben, KK; Kiemeney, LA; Vermeulen, SH; Wiencke, JK; Walsh, KM; Wrensch, M; Rice, T; Turnbull, C; Litchfield, K; Paternoster, L; Standl, M; Abecasis, GR; SanGiovanni, JP; Li, Y; Mijatovic, V; Sapkota, Y; Low, S-K; Zondervan, KT; Montgomery, GW; Nyholt, DR; van Heel, DA; Hunt, K; Arking, DE; Ashar, FN; Sotoodehnia, N; Woo, D; Rosand, J; Comeau, ME; Brown, WM; Silverman, EK; Hokanson, JE; Cho, MH; Hui, J; Ferreira, MA; Thompson, PJ; Morrison, AC; Felix, JF; Smith, NL; Christiano, AM; Petukhova, L; Betz, RC; Fan, X; Zhang, X; Zhu, C; Langefeld, CD; Thompson, SD; Wang, F; Lin, X; Schwartz, DA; Fingerlin, T; Rotter, JI; Cotch, MF; Jensen, RA; Munz, M; Dommisch, H; Schaefer, AS; Han, F; Ollila, HM; Hillary, RP; Albagha, O; Ralston, SH; Zeng, C; Zheng, W; Shu, X-O; Reis, A; Uebe, S; Hüffmeier, U; Kawamura, Y; Otowa, T; Sasaki, T; Hibberd, ML; Davila, S; Xie, G; Siminovitch, K; Bei, J-X; Zeng, Y-X; Försti, A; Chen, B; Landi, S; Franke, A; Fischer, A; Ellinghaus, D; Flores, C; Noth, I; Ma, S-F; Foo, JN; Liu, J; Kim, J-W; Cox, DG; Delattre, O; Mirabeau, O; Skibola, CF; Tang, CS; Garcia-Barcelo, M; Chang, K-P; Su, W-H; Chang, Y-S; Martin, NG; Gordon, S; Wade, TD; Lee, C; Kubo, M; Cha, P-C; Nakamura, Y; Levy, D; Kimura, M; Hwang, S-J; Hunt, S; Spector, T; Soranzo, N; Manichaikul, AW; Barr, RG; Kahali, B; Speliotes, E; Yerges-Armstrong, LM; Cheng, C-Y; Jonas, JB; Wong, TY; Fogh, I; Lin, K; Powell, JF; Rice, K; Relton, CL; Martin, RM; Davey Smith, G (2017-05)
      Importance:The causal direction and magnitude of the association between telomere length and incidence of cancer and non-neoplastic diseases is uncertain owing to the susceptibility of observational studies to confounding ...
    • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. 

      Filipits, M; Dafni, U; Gnant, M; Polydoropoulou, V; Hills, M; Kiermaier, A; de Azambuja, E; Larsimont, D; Rojo, F; Viale, G; Toi, M; Harbeck, N; Prichard, KI; Gelber, RD; Dinh, P; Zardavas, D; Leyland-Jones, B; Piccart-Gebhart, MJ; Dowsett, M; TransHERA investigators (2018-07)
      Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ...
    • Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. 

      Büchel, G; Carstensen, A; Mak, K-Y; Roeschert, I; Leen, E; Sumara, O; Hofstetter, J; Herold, S; Kalb, J; Baluapuri, A; Poon, E; Kwok, C; Chesler, L; Maric, HM; Rickman, DS; Wolf, E; Bayliss, R; Walz, S; Eilers, M (2017-12)
      MYC proteins bind globally to active promoters and promote transcriptional elongation by RNA polymerase II (Pol II). To identify effector proteins that mediate this function, we performed mass spectrometry on N-MYC complexes ...
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      BACKGROUND:Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM protein ...
    • ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele 

      Matutes, E (2012-01)
      Ataxia telangiectasia patients, with constitutional bi-allelic ATM mutations, have a marked risk of lymphoid tumors and ATM mutation carriers have a smaller risk of cancer. Sporadic ATM mutations occur in 10-20% of chronic ...
    • ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma. 

      Foster, H; Ruiz, EJ; Moore, C; Stamp, GWH; Nye, EL; Li, N; Pan, Y; He, Y; Downward, J; Behrens, A (2019-10)
      Tumor cells proliferate rapidly and thus are frequently subjected to replication stress and the risk of incomplete duplication of the genome. Fragile sites are replicated late, making them more vulnerable to damage when ...
    • ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. 

      Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; Patin, EC; Pearson, A; Smith, HG; Paget, JTE; Patel, RR; Foo, S; Bozhanova, G; Ragulan, C; Fontana, E; Desai, K; Wilkins, AC; Sadanandam, A; Melcher, A; McLaughlin, M; Harrington, KJ (2019-06)
      PURPOSE:ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the tumor ...
    • ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. 

      Williamson, CT; Miller, R; Pemberton, HN; Jones, SE; Campbell, J; Konde, A; Badham, N; Rafiq, R; Brough, R; Gulati, A; Ryan, CJ; Francis, J; Vermulen, PB; Reynolds, AR; Reaper, PM; Pollard, JR; Ashworth, A; Lord, CJ (2016-12-13)
      Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in ARID1A represent one of the most common molecular alterations ...
    • ATR Is a Therapeutic Target in Synovial Sarcoma. 

      Jones, SE; Fleuren, EDG; Frankum, J; Konde, A; Williamson, CT; Krastev, DB; Pemberton, HN; Campbell, J; Gulati, A; Elliott, R; Menon, M; Selfe, JL; Brough, R; Pettitt, SJ; Niedzwiedz, W; van der Graaf, WTA; Shipley, J; Ashworth, A; Lord, CJ (2017-12)
      Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we ...
    • Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. 

      Vijayakrishnan, J; Studd, J; Broderick, P; Kinnersley, B; Holroyd, A; Law, PJ; Kumar, R; Allan, JM; Harrison, CJ; Moorman, AV; Vora, A; Roman, E; Rachakonda, S; Kinsey, SE; Sheridan, E; Thompson, PD; Irving, JA; Koehler, R; Hoffmann, P; Nöthen, MM; Heilmann-Heimbach, S; Jöckel, K-H; Easton, DF; Pharaoh, PDP; Dunning, AM; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Greaves, M; Zimmerman, M; Bartram, CR; Schrappe, M; Stanulla, M; Hemminki, K; Houlston, RS (2019-01-21)
      The original version of this Article contained an error in the spelling of a member of the PRACTICAL Consortium, Manuela Gago-Dominguez, which was incorrectly given as Manuela Gago Dominguez. This has now been corrected ...
    • Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS (2019-01-10)
      The original version of this Article contained an error in the spelling of a member of the PRACTICAL Consortium, Manuela Gago-Dominguez, which was incorrectly given as Manuela Gago Dominguez. This has now been corrected ...
    • Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. 

      Sonnenblick, A; Bailey, A; Uziely, B; Untch, M; Smith, I; Gianni, L; Baselga, J; Jackisch, C; Cameron, D; Bell, R; Zardavas, D; Al-Sakaff, N; Gelber, RD; Dowsett, M; Leyland-Jones, B; Piccart-Gebhart, MJ; DE Azambuja, E (2019-02)
      BACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based ...
    • Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells. 

      Wang, Y; Xiong, H; Liu, D; Hill, C; Ertay, A; Li, J; Zou, Y; Miller, P; White, E; Downward, J; Goldin, RD; Yuan, X; Lu, X (2019-05)
      Macroautophagy/autophagy inhibition is a novel anticancer therapeutic strategy, especially for tumors driven by mutant RAS. Here, we demonstrate that autophagy inhibition in RAS-mutated cells induces epithelial-mesenchymal ...
    • Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. 

      Hill, C; Li, J; Liu, D; Conforti, F; Brereton, CJ; Yao, L; Zhou, Y; Alzetani, A; Chee, SJ; Marshall, BG; Fletcher, SV; Hancock, D; Ottensmeier, CH; Steele, AJ; Downward, J; Richeldi, L; Lu, X; Davies, DE; Jones, MG; Wang, Y (2019-08-07)
      Idiopathic pulmonary fibrosis (IPF), the prototypic progressive fibrotic interstitial lung disease, is thought to be a consequence of repetitive micro-injuries to an ageing, susceptible alveolar epithelium. Ageing is a ...
    • Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. 

      Smrke, A; Gennatas, S; Huang, P; Jones, RL (2020-08)
      Gastrointestinal stromal tumors (GIST) can be molecularly classified based on different subtypes including mutations in KIT and PDGFRA. Patients with PDGFRA mutations are an important subgroup that commonly arise in the ...
    • B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia 

      Ruchlemer, R; Parry-Jones, N; Brito-Babapulle, V; Attolico, I; Wotherspoon, AC; Matutes, E; Catovsky, D (BLACKWELL PUBLISHING LTD, 2004-05)
      We reviewed eight cases that were diagnosed before 1995 with B-prolymphocytic leukaemia (B-PLL) harbouring t(11;14)(q13;q32) and/or cyclin D1 staining. Thirteen B-PLL patients without t(11;14) were selected as controls. ...
    • Baculum morphology predicts reproductive success of male house mice under sexual selection 

      Sherborne, Amy (2013-06)
      Background: Diversity in penile morphology is characterised by extraordinary variation in the size and shape of the baculum (penis bone) found in many mammals. Although functionally enigmatic, diversity in baculum form is ...
    • Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. 

      Cremolini, C; Benelli, M; Fontana, E; Pagani, F; Rossini, D; Fucà, G; Busico, A; Conca, E; Di Donato, S; Loupakis, F; Schirripa, M; Lonardi, S; Borelli, B; Ongaro, E; Eason, K; Morano, F; Casagrande, M; Fassan, M; Sadanandam, A; de Braud, F; Falcone, A; Pietrantonio, F (2019-01)
      Objective:Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has usually ...
    • Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. 

      Xu, K; Guidez, F; Glasow, A; Chung, D; Petrie, K; Stegmaier, K; Wang, K-K; Zhang, J; Jing, Y; Zelent, A; Waxman, S (2005-09)
      Differentiation induction is an effective therapy for acute promyelocytic leukemia (APL), which dramatically responds to all-trans-retinoic acid (ATRA). Recent studies have indicated that combinatorial use of retinoid and ...
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors. 

      Chabanon, RM; Soria, J-C; Lord, CJ; Postel-Vinay, S (2019-01)
      Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, ...